Furthermore, our findings suggest that the combination of immune checkpoint inhibitors and ATR inhibitors to which tumours with the aforementioned GAs are sensitive to in preclinical models and early clinical data, warrants further investigation. This evidence concerns the gene ATR and neoplasm.